Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis' Entresto Blockbuster Status On Track After CHMP Backing

This article was originally published in Scrip

Executive Summary

Novartis' heart failure pill Entresto is already predicted to reach blockbuster status on the strength of its July approval in the US and now formal recommendation by CHMP in Europe for patients with reduced ejection fraction – representing some 50% of chronic heart failure patients - but those prospects could soar if an ongoing Phase III study presents the opportunity to eventually move the agent into the other half of chronic heart failure patients, those having preserved ejection fraction.



Related Companies